Company Filing History:
Years Active: 2010
Title: Jean-Phillipe Ducoux: Innovator in Cannabinoid Research
Introduction
Jean-Phillipe Ducoux is a notable inventor based in Combaillaux, France. He has made significant contributions to the field of cannabinoid research, particularly in the development of compounds that act as cannabinoid CB1 receptor antagonists. His work is essential in understanding and potentially treating various conditions related to cannabinoid receptors.
Latest Patents
Ducoux holds a patent for N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea] derivatives as cannabinoid CB1 receptor antagonists. This invention concerns compounds of formula (I), wherein X, R, R, R, R, and R are defined within the patent. The invention also outlines a method for preparing these compounds and their application as cannabinoid CB1 receptor antagonists.
Career Highlights
Jean-Phillipe Ducoux is associated with Sanofi-Aventis, a leading global biopharmaceutical company. His role at the company has allowed him to focus on innovative research and development in the pharmaceutical sector. His expertise in cannabinoid research has positioned him as a valuable asset in the field.
Collaborations
Ducoux has collaborated with notable colleagues, including Francis Barth and Christian Congy. These collaborations have fostered a productive environment for innovation and research in cannabinoid-related studies.
Conclusion
Jean-Phillipe Ducoux's contributions to cannabinoid research through his patent and work at Sanofi-Aventis highlight his importance in the field. His innovative approach to developing cannabinoid CB1 receptor antagonists showcases the potential for advancements in medical treatments.